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abstract
Keywords:

Human immunodeficiency virus (HIV) epidemics in Asia have been initially driven through

Harm reduction

injection drug use and the use of shared needles and syringes. Molecular epidemiological

HIV prevention

work has shown that where there is heroin trafficking and use, there is also HIV. Given the

Opiate substitution programs

often strict enforcement of national antinarcotic laws, harm reduction responses to HIV
infections driven by injection drug use have been historically slow. As it became clear that
preventing HIV meant embracing harm reduction, many countries in the region have
adopted harm reduction as part of their national acquired immunodeficiency syndrome
(AIDS) strategy and increasingly as part of their national drug strategy. Initial successes
have proven that harm reduction, as it pertains to HIV among injection drug users (IDUs),
can and does work in Asia. These initial successes have led to more comprehensive scaleup of other essential components of HIV prevention among IDUs, including increased
availability of opiate substitution programs. Still, multiple challenges remain because
overall coverage of services in the region remains poor. Changes in the availability and
patterns of use of drugs, including the exponential increase in the use of amphetaminetype stimulants, are providing ongoing challenges to both the law enforcement and public health sectors. This paper reflects on the history of harm reduction in Asia and the
shifting trends forcing policy makers to adapt and expand harm reduction strategies to
include an ever widening approach to criminal justice, policing, public health, and human
rights.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

Harm reduction responses to drug use and human immunodeficiency virus (HIV) infection in Asia began over 20 years
ago. This paper describes the evolution of harm reduction
through a historical analysis of four interconnected themes:

harm reduction programs, research, policy, and advocacy.
This paper then describes the need for an expanded definition
and construction of harm reduction in order to meet the
challenges posed by changing trends in drug availability and
use, particularly regarding methamphetamine. In this
expanded definition, multisectoral partnerships across law
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enforcement, criminal justice, the health sector, and civil society organizations would work toward reducing all harms
associated with drug use, including the widespread arrest and
incarceration of drug users. Only a comprehensive revision
and expansion of how we implement harm reduction in Asia
will allow harm reduction to remain the cornerstone element
in the reduction of drug-related harm for the next 20 years.

2.
Asia

Harm reduction projects and programs in

In response to widespread needle sharing among injection
drug users (IDUs), the first needle exchange project in Asia
was set up in Nepal’s Kathmandu Valley in 1991 by the Life
Saving and Life Giving Organization [1]. Since then, there has
been tremendous expansion, progress, and innovation in the
delivery of harm reduction projects and programs in a variety
of complex settings across Asia. The Mae Chan Clinic in
northern Thailand set up the first multisite needle and syringe
exchange project at three sites in 1992, and The Society for
Service to Urban Poverty (SHARAN) established the first sublingual buprenorphine project in 1993 in India. The acquired
immunodeficiency syndrome (AIDS) Surveillance and Education Project began distributing needles to methamphetamine
injectors in the Philippines in 1995. SHALOM began delivering
needles and conducting outreach to respond to the devastating epidemic in Manipur, in conflict-riddled northeastern
India, in 1995. The Pink Triangle (forerunner to the Malaysian
AIDS Council) began street outreach in a red light area in
Chow Kit (in Kuala Lumpur) in 1995 [2].
Almost all of these early harm reduction projects shared a
similar set of characteristics. The projects were initiated and
driven by nongovernment organizations (NGOs) and operated
in isolation from, and often in conflict with, mainstream
government approaches to drug use. This led to a constant
state of tension between public security, public health, and
the community. The projects were often underfunded or at
risk of funding gaps, and this perilous existence relied upon
extensive and exhausting advocacy. This situation began to
change during the late 1990s when harm reduction concepts
began to become entrenched in national HIV/AIDS programs
and strategic planning in some Asian countries. Assisting this
change were the donor agencies’ support and funding for
government agencies to adopt harm reduction programs.
As momentum for harm reduction grew, the United Nations (UN) formed its first iteration of the UN Regional Task
Force on Injecting Drug Use and HIV in 1997 [3]. The first of the
AusAID regional projects concentrating on policy and advocacy began working across three countries in Asia [4], and
donors supported the first national-level program scaling up
coverage of needles and syringes in Nepal [5].

3.
Influence of research on harm reduction
in Asia
The early harm reduction projects led by NGOs in Asia also led
to the earliest research efforts investigating HIV and drug use
in Asia. Partnerships between NGOs and international

research institutes led the first studies determining HIV
prevalence among IDUs. These papers formed comparative
baselines for research to show that harm reduction projects
implemented by NGOs led to a reduction in HIV risk behavior
among IDUs and confirmed that harm reduction could work in
the Asian context.
A growing research interest in the HIV epidemic among
drug users in Asia led to an increasing number of United
States (US) National Institute on Drug Abuse/National Institutes of Health (NIDA/NIH) meetings taking place in Asia, as
well as an increase in the number of grants given to research
collaborations between Asian and US research institutes. The
HIV Prevention Trial Network and the HIV Vaccine Trial
Network funded several of these initial collaborations, which
included peer-based behavioral intervention/control HIV
prevention studies [6], as well as a large study examining the
role of Suboxone in HIV prevention among injecting opiate
users [7]. The growth of national research networks, such as
the Thai Academic Substance Abuse Network, highlighted
that national governments were increasingly interested in
drug use and its implications for individual and public health
as well as for public security.
Molecular epidemiology studies began proving that HIV
epidemics followed heroin trafficking routes across Asia. This
research highlighted the role of complex political environments and porous borders on the mixing of HIV viral subtypes.
It also indicated that for harm reduction programs to grow in
complex environments they would need to be supported by
key stakeholders across the political, security, and health
sectors. Research efforts began focusing on showing how
harm reduction projects could be delivered across borders
between two countries [8]. These efforts led to the programming of broader regional cross-border harm reduction across
the Greater Mekong Subregion [9].

4.
The rise of methamphetamine use and
the implications for harm reduction and its
research
While harm reduction programs and research continued to
predominately focus on injecting drug use and HIV, patterns
of drug use in Asia were drastically changing. Across Asia, the
availability and use of methamphetamine exponentially
increased beginning in 1996, and by 2009, rates of methamphetamine use had overtaken the use of heroin in many
countries across Asia [10]. Because most methamphetamine
use was through noninjecting methods, the links between the
drug’s use and HIV were less clear than with injecting drug
use. The implications for individual and public health as well
as public security, however, extended beyond just HIV risk
and highlighted the need for an expanded definition of harm
reduction and, indeed, the research agenda [11].
Specific harm reduction research in the context of methamphetamine use in Asia only began after nationwide
household surveys described its widespread use [12]. Some
clinical studies followed examining methamphetamine
withdrawal and the role of cognitive behavioral therapy in
promoting cessation of use and prevention of relapse [13].
Given the lack of substitution therapy for methamphetamine
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use, researchers needed to design and explore a harm reduction approach to methamphetamine in the Asian context. A
large peer-based behavioral intervention/control trial conducted in northern Thailand showed that reductions in
methamphetamine use and uptake in condom use could be
influenced by peer-based methods [14]. This study has led to a
larger community mobilization study exploring how the root
structural causes of methamphetamine availability and use
could be identified and addressed to reduce methamphetamine use [15].
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only prevent HIV but can have major benefits for the criminal
justice system as well as the community. Evidence that harm
reduction can decrease crime as well as improve a variety of
health outcomes makes a strong argument. HIV can no longer
remain our only harm reduction research endpoint. In Asia,
we need to explore the science of the enabling environment so
that an expanded harm reduction approach results in an
expanded number of multisectoral key stakeholders engaged
and committed to its implementation.
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